Disc Medicine (IRON) grants director Liam Ratcliffe 6,212 stock options

Rhea-AI Filing Summary

Disc Medicine, Inc. director Liam Ratcliffe received a grant of stock options covering 6,212 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036.

These options vest on the earlier of the company’s 2027 annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues to serve through that vesting date. Following this grant, he holds 6,212 stock options directly, reflecting a compensation-related award rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ratcliffe Liam

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,212	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,212 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 6,212 options Exercise price: $70.79 per share Expiration date: June 17, 2036 +2 more

5 metrics

Stock options granted 6,212 options Grant to director Liam Ratcliffe

Exercise price $70.79 per share Conversion or exercise price of options

Expiration date June 17, 2036 Option expiration for Ratcliffe grant

Underlying shares 6,212 shares Common stock underlying the options

Holdings after transaction 6,212 options Total derivative holdings following grant

Key Terms

Stock Option (Right to Buy), exercise price, vest, annual meeting

4 terms

Stock Option (Right to Buy) financial

"Security title is listed as "Stock Option (Right to Buy)""

exercise price financial

"The options carry a conversion or exercise price of $70.79"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The shares underlying this option vest upon the first to occur of..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting financial

"Vesting may occur on the date of the Company’s 2027 annual meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:01 PM Accepted by SEC EDGAR 06/23/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ratcliffe Liam

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$70.79	06/18/2026		A		6,212		(1)	06/17/2036	Common Stock	6,212	$0	6,212	D

Explanation of Responses:

1. The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Disc Medicine (IRON) report for Liam Ratcliffe?

Disc Medicine reported that director Liam Ratcliffe received a grant of 6,212 stock options. These options give him the right to buy common shares at a fixed exercise price as part of his director compensation package, rather than reflecting an open-market purchase or sale.

How many Disc Medicine (IRON) stock options were granted to Liam Ratcliffe?

Liam Ratcliffe was granted 6,212 stock options. Each option corresponds to one share of Disc Medicine common stock, providing potential future ownership if exercised. After this award, the filing shows he directly holds 6,212 options tied to the company’s common shares.

What is the exercise price of Liam Ratcliffe’s Disc Medicine (IRON) stock options?

The stock options granted to Liam Ratcliffe have an exercise price of $70.79 per share. This means he can buy Disc Medicine common stock at $70.79 if he exercises the options once they vest and before they expire in 2036.

When do Liam Ratcliffe’s Disc Medicine (IRON) stock options vest?

The options vest on the earlier of the company’s 2027 annual stockholder meeting or the one-year anniversary of the grant date. Vesting also depends on Ratcliffe continuing to serve through the vesting date, aligning the award with ongoing board service.

When do Liam Ratcliffe’s Disc Medicine (IRON) stock options expire?

The options granted to Liam Ratcliffe expire on June 17, 2036. If he does not exercise them before this expiration date, they will lapse and can no longer be used to purchase Disc Medicine common stock at the $70.79 exercise price.

Is Liam Ratcliffe’s Disc Medicine (IRON) Form 4 a stock buy or sell?

The Form 4 reflects an acquisition of stock options as a grant, not a market buy or sell of shares. It records a compensation-related award that may lead to future share purchases if Ratcliffe chooses to exercise the options after they vest.